Jobs to go at Exscientia

22 May 2024
exscientia_big

AI-driven precision medicine company Exscientia (Nasdaq: EXAI) has announced a headcount reduction of between 20% and 25%.

The jobs will go at the UK firm this year, impacting some areas of target identification, precision medicine, experimentation, engineering and infrastructure.

The redundancies are part of a series of efficiency measures through the rest of the year that are designed to streamline the company’s operations, which it expects to result in annual savings of $40 million or more beginning in 2025.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology